| Hepatic Encephalopathy |
NCT05128305: Integrated Traditional Chinese and Clinical Medicine for Chronic Hepatitis B and Its Complication |
|
|
| Not yet recruiting | 3 | 276 | RoW | traditional Chinese medicine1 and traditional Chinese medicine 2, traditional Chinese medicine1 simulant and traditional Chinese medicine 2 simulant | Qianfoshan Hospital | Hepatic Encephalopathy, Cirrhosis, Liver, Portosystemic Shunt | 06/22 | 12/22 | | |
ACTRN12619000891123: The impact of continuous terlipressin infusion on complications of end-stage liver disease |
|
|
| Completed | 3 | 30 | | | Austin Health, Mallinckrodt Pharmaceuticals | Cirrhosis, Sarcopaenia, Inflammation, Malnutrition, Ascites, Infection, Immune function, Hepatic encephalopathy | | | | |
2017-002677-19: Biological mechanisms of Acute on Chronic Liver Failure (ACLF) and Mechanisms of Action of Plasma Exchange with Human Serum Albumin 5% in Subjects with cirrhosis with systemic inflammation and ACLF |
|
|
| Not yet recruiting | 3 | 250 | Europe | Albutein 5%, [B05AA01], Solution for infusion, Human Albumin Grifols 50g/l | Instituto Grifols S.A., INSTITUTO GRIFOLS, S.A., Instituto Grifols S.A. | Group 1 and 2:Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or duringhospitalization Group 3: Subject with cirrhosis hospitalized for Acute decompensation of cirrhosis (ascites, hepatic encephalopathy [HE], gastrointestinal hemorrhage, and/or bacterial infections), Group 1 and 2: Subjects with cirrhosis and diagnosed Acute-on-Chronic Liver FailureGroup 3: Subjects with cirrhosis without diagnosed Acute-on-Chronic Liver Failure, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT04244877: Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility |
|
|
| Withdrawn | 3 | 20 | NA | Rifaximin, Xifaxan | MetroHealth Medical Center | Cirrhosis, Liver, Minimal Hepatic Encephalopathy, Small Intestinal Bacterial Overgrowth, Gastrointestinal Motility Disorder | 05/23 | 12/23 | | |
NCT05754996: Comparing Nifuroxazide Plus Lactulose With Lactulose Alone in the Treatment of Hepatic Encephalopathy |
|
|
| Recruiting | 3 | 102 | RoW | Nifuroxazide, Lactulose, Rifaximin 550Mg Tab | Cairo University | Hepatic Encephalopathy | 12/24 | 12/24 | | |
RED-C-3131, NCT05071716: Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis |
|
|
| Active, not recruiting | 3 | 524 | Canada, US, RoW | Rifaximin SSD, Placebo | Bausch Health Americas, Inc. | Hepatic Encephalopathy | 09/25 | 09/25 | | |
RED-C-3132, NCT05297448: Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis |
|
|
| Active, not recruiting | 3 | 466 | Europe, Canada, US, RoW | Rifaximin SSD, Placebo | Bausch Health Americas, Inc. | Hepatic Encephalopathy | 01/26 | 01/26 | | |
NCT04161053: Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy |
|
|
| Recruiting | 3 | 60 | RoW | Rifaximin, Gastrobiotic, Trencedia, Nitazoxanide, Nanazoxid | Tanta University | Hepatic Encephalopathy | 11/28 | 12/28 | | |
NCT05511766: Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis |
|
|
| Recruiting | 2/3 | 150 | RoW | Allopurinol 300 MG, zyloric, Atorvastatin 20mg, Placebo | Tanta University | Cirrhosis, Hepatic Encephalopathy, Ascites, Varices, SBP - Spontaneous Bacterial Peritonitis | 04/24 | 01/25 | | |
ChiCTR2100052806: Treatment of minimal hepatic encephalopathy with berberine and caffeic acid |
|
|
| Not yet recruiting | 2/3 | 90 | | Berberine hydrochloride tablets 0.3g oral taken TID(three times a day) ;Caffeic acid tablets 0.3g oral taken TID ;General life guidance and treatment of non-hepatic encephalopathy | Huadong Hospital Affiliated to Fudan University; Huadong Hospital Affiliated to Fudan University, Huadong Hospital Affiliated to Fudan University | Minimal hepatic encephalopathy | | | | |
